InMed Pharmaceuticals completes 1-for-10 share consolidation
INM•InMed Pharmaceuticals completed a 1-for-10 common share consolidation on November 4, 2026, reducing outstanding shares from 5,493,735 to approximately 549,374. The company changed its name to Mentari Therapeutics, with post-consolidation trading under symbol INM expected to begin November 5.
1. Share consolidation completed
InMed Pharmaceuticals completed a 1-for-10 common share consolidation on November 4, 2026, reducing outstanding shares from 5,493,735 to approximately 549,374. The company also changed its name to Mentari Therapeutics, effective November 4. Post-consolidation trading under the existing symbol INM is expected to begin November 5 on the Nasdaq Capital Market.
